Bristol Myers Squibb gets EC approval for Zeposia to treat multiple sclerosis
With the EC approval, Zeposia becomes the only approved S1P receptor modulator available for the treatment of RRMS…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
28 May 20
With the EC approval, Zeposia becomes the only approved S1P receptor modulator available for the treatment of RRMS…
27 May 20
The safety and efficacy of artesunate was primarily evaluated in a randomised controlled trial in Asia and a…
27 May 20
The MHRA opinion will support the use of remdesivir to treat patients hospitalised with severe Covid-19 infection who…
26 May 20
Results from the Phase 3 ALTA 1L Trial demonstrated ALUNBRIG as a better treatment for ALK+ Metastatic NSCLC,…
Analysts at GlobalData believe the decrease in FDA drug approvals is due to a US government shutdown in…
21 May 20
The FDA approval was supported by results from the Phase 3 PROfound study that evaluated the efficacy and…
20 May 20
Zolgensma showed therapeutic benefit in pre-symptomatic and symptomatic SMA, including prolonged event-free survival and achievement of motor milestones
19 May 20
Enhertu is indicated for the treatment of metastatic in patients whose tumours have a HER2 mutation and with…
18 May 20
QINLOCK has been indicated for GIST in adult patients who have received prior treatment with three or more…
15 May 20
The approval is based on results of from Phase 3 ECHELON-2 trial, which showed that treatment with ADCETRIS…